Angelini Pharma at EAN Congress 2025: rethinking seizure control, together
From 21 to 24 June, Helsinki will host the 11th edition of the European Academy of Neurology (EAN) Congress, where the international scientific community will gather to explore the central theme of Neurology within Society. Once again, Angelini Pharma will take part in the event with a strong scientific and educational presence, reflecting its long-standing commitment to improving outcomes for people living with epilepsy.
A renewed focus on subcontrolled epilepsy
The company’s core contribution to this year’s edition is the Satellite Symposium, scheduled for Monday, June 23rd, from 12:45 to 13:45. Titled Uncontrolled epilepsy in early lines: Rethinking epilepsy management, the session will be moderated by Senior Prof. Elinor Ben-Menachem, Professor Emeritus in Neurology and Epilepsy, Sahlgrenska Academy, Göteborg University, Sweden, and will bring together leading voices in the field to discuss how we can better identify and manage epilepsy that remains uncontrolled and subcontrolled.
Álvaro Beltrán Corbellini, MD, MSc, Epilepsy Unit, Hospital Ruber Internacional, Madrid, Spain, will open the symposium with a presentation titled Recognizing the Unseen: How to Identify and Address Subcontrolled Epilepsy in Clinical Practice. His contribution will address the concept of "subcontrol" and how its signs can often go unrecognized in day-to-day clinical settings, leading to persistent patient vulnerability.
Next, Prof. Dr. Bettina Schmitz, Department of Neurology and Center for Epilepsy, Vivantes-Humboldt-Klinikum, Berlin, Germany, will deliver Redefining Seizure Control – Evidence, Experience, and the Road Ahead, an in-depth overview of the long-term clinical experience and real-world evidence surrounding cenobamate, highlighting its role in enhancing seizure control and redefining therapeutic strategies for patients who continue to experience uncontrolled focal seizures after 2 previous ASMs.
New evidence that connects seizure control to broader brain health outcomes
In line with the themes explored during the symposium, Angelini Pharma will present new clinical data that reinforce the importance of achieving and sustaining seizure freedom. Notably, recent findings show that adjunctive treatment with cenobamate is associated with a significant reduction in the risk of Sudden Unexpected Death in Epilepsy (SUDEP)—a critical, yet often under-recognised, consequence of uncontrolled seizures.
Other studies further explore the bidirectional relationship between epilepsy and depression. Using artificial intelligence and real-world datasets, researchers identified early risk indicators and overlapping clinical profiles—offering a data-driven approach to personalized brain health management, and emphasizing the need to treat epilepsy as a condition that extends beyond seizures alone.
A retrospective analysis conducted on U.S. patients also demonstrated that treatment with cenobamate is associated with a notable reduction in healthcare resource utilization, including epilepsy-related hospitalizations and emergency room visits. These findings speak not only to the therapy’s clinical benefits, but also to its potential in supporting more efficient and sustainable healthcare systems.
Supporting scientific dialogue across the EAN programme
Complementing the symposium, Angelini Pharma will also participate in the EAN Scientific Theatre with a short-format educational session. The Forum Talk, titled Brain Health in Epilepsy: The Burden of Uncontrolled Seizures, will take place on Monday, June 23rd, from 10:00 to 10:15. Chaired by John Paul Leach, Senior Clinical Fellow at Angelini Pharma, with a presentation by Dr. Marco Mula MD PhD FRCP FEAN, St George’s University Hospitals London, United Kingdom , the talk will reflect on how seizure control—or the lack thereof—can influence not only neurological progression, but also cognitive function, mental health, and quality of life.
Angelini Pharma: a shared mission to improve lives
Angelini Pharma’s participation in EAN 2025 embodies its ongoing mission to foster meaningful scientific exchange, support healthcare professionals with the latest evidence, and drive forward innovations that can transform the standard of care. By elevating the conversation around uncontrolled and subcontrolled epilepsy and championing solutions that address its wide-reaching impact, the company continues to walk alongside the medical community in advancing brain health for all.